Abstract: Novel antibiotic stalobacins H-1 and I-1 having physico-chemical properties as shown in Table 4 are provided, which are excellent antibiotics showing marked effects on Gram-positive bacteria.

Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt, or a hydrate thereof, a process for preparing said compound, and a pharmaceutical composition having antiviral activity which comprise said compound.

Abstract: A sewing machine which includes a main shaft motor for driving a main shaft; a needle bar for moving up and down by rotation of the main shaft motor; a thread exchanging mechanism, having a swinging member swingable by rotation of the main shaft motor, for exchanging a thread by moving a thread barrel having an opening through which a thread is passed, from a standby position to an exchange position; and a controller for controlling the rotation of the main shaft motor.

Abstract: Novel antibiotic stalobacins A to I having physico-chemical properties as shown in Tables 1 to 4 are provided, which are excellent antibiotics showing marked effects on Gram-positive bacteria.

Abstract: The present invention relates to a novel aldose reductase inhibitor of the formula: ##STR1## wherein X is methylene or carbonyl;R is ##STR2## R.sup.1, R.sup.2, R.sup.3, and R.sup.4 each is hydrogen or lower alkyl, to a method for producing the inhibitor by culturing Crucibulum sp. RF-3817 or its variants, and to an agent for inhibiting an aldose reductase comprising the inhibitor.

Abstract: The present invention relates to a compound represented by the formula I: ##STR1## which was isolated from the culture of Streptomyces prunicolor PA-48153 and has biological activity such as immunosuppressive activity, antitumor activity and antifungal activity.

Abstract: The present invention relates to an aldose reductase inhibitor represented by the formula: ##STR1## wherein R.sub.1 is (CH.sub.2).sub.2 COOH and R.sub.2 is phenyl or p-hydroxyphenyl, or R.sub.1 and R.sub.2 are combined together to form a group of the formula: ##STR2## which was isolated from the fermentation products of Chaetomella circinoseta RF-3192.

Abstract: A compound of the formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are --COOR.sup.4, --COOR.sup.5, and --COOR.sup.6, respectively; R.sup.4, R.sup.5, and R.sup.6 each is hydrogen, lower alkyl, or alkali metal; W is hydroxyl; X, Y, and Z each is hydrogen or hydroxyl; a dotted line indicates the presence or absence of a single bond; or where W/R.sup.3, X/R.sup.1, and/or Z/R.sup.3 may be combined together, a lactone is formed, which compound is useful as a phospholipase A.sub.2 inhibitor. Process for the production of the compound (I) and a cell culture of a microorganism Circinotrichum falcatisporum RF-641 producing the same are also provided.

Abstract: A cyclic tetrapeptide having the formula (I): ##STR1## wherein n is 4 or 3 and a process for preparing the above cyclic tetrapeptide. The cyclic tetrapeptide of the present invention inhibits transformation of cells caused by oncogenes and possesses activities for recovering to a normal cell and for inhibiting proliferation of carcinoma cells. Therefore, the cyclic tetrapeptide of the present invention is useful for an active ingredient of an antitumor agent.

Abstract: A compound of the formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are --COOR.sup.4, --COOR.sup.5, and --COOR.sup.6, respectively; R.sup.4, R.sup.5, and R.sup.6 each is hydrogen, lower alkyl, or alkali metal; W is hydroxyl; X, Y, and Z each is hydrogen or hydroxyl; a dotted line indicates the presence or absence of a single bond; or where W/R.sup.3, X/R.sup.1, and/or Z/R.sup.3 may be combined together, a lactone is formed, which compound is useful as a phospholipase A.sub.2 inhibitor. Process for the production of the compound (I) and a cell culture of a microorganism Circinotrichum falcatisporum RF-641 producing the same are also provided.

Abstract: Glycopeptide antibiotics PA-45052 which are produced by Nocardia orientalis PA-45052, show potent activity against gram-positive bacteria, especially against methicillin-resistant bacteria, and stimulate growth of animals.

Abstract: A compound of the formula: ##STR1## wherein the wave line means .alpha.-bond or .beta.-bond, which compound is useful as a phospholipase A.sub.2 inhibitor. Process for the production of the compound, pharmaceutical composition containing the compound, and a cell culture of a microorganism Thielavia terricola RF-143 producing the compound are also provided.

Abstract: The compounds of the formula: ##STR1## wherein R is ##STR2## or H, wherein X is NH.sub.2 and Y is CH.sub.3 ; or X is OH and Y is H, and their pharmaceutically acceptable salts. The compounds have a potent activity against gram-positive bacteria, especially, methicillin-resistant bacteria.

Abstract: Antibiotics DO-248-A and DO-248-B of the following Formula I: ##STR1## wherein R is ethyl or isopropyl, have antibacterial activity against acid-fast bacteria. DO-248-A, DO-248-B, or their pharmaceutically acceptable salts are, as an active ingredient of anti-fast-acid drugs, orally or parenterally administered to human beings or animal. DO-248-A and DO-248-B are prepared by incubating an antibiotic DO-248-A- and/or DO-248-B-producing microorganism belonging to genus Streptoverticillium in a medium and recovering antibiotic DO-248-A and/or DO-248-B from the culture broth.

Abstract: .beta.-Galactosidase inhibitors GT-2558, GT-2558-A, and GT-2558-B produced by a strain Streptomyces lydicus PA-5726, and their derivatives, acetyl-GT-2558-A and acetyl-GT-2558-B, useful as diagnostatic aid in .beta.-galactosidase deficiency, used in purification of enzymes, in research of new .beta.-galactosidase, in controlling sweetness of lactose-containing foods and in fermentation industry.

Abstract: New antibiotics having .beta.-lactamase inhibitory activity, PA-41746-B and C of the formula ##STR1## wherein R is carboxymethylsulfinyl (PA-41746-B) or formylsulfinyl (PA-41746-C) and the pharmaceutically acceptable salts being useful as a medicament, a veterinary drug and a disinfectant for inhibiting the growth of gram-positive and gram-negative pathogenic microorganisms and a process for preparing the same, being characterized by cultivating Streptomyces pluracidomyceticus in a suitable medium and isolating PA-41746-B and/or PA-41746-C from the culture broth.

Abstract: A new process for preparing thienamycin, a known antibiotic useful as a medicament and veterinary drug, characterized by cultivating Streptomyces penemifaciens sp. nov. in a suitable medium and recovering thienamycin from the fermentation broth.

Abstract: A new antibiotic having .beta.-lactamase inhibitory activity, PA-31088-IV, being useful as a medicament and a veterinary drug for inhibiting the growth of gram-positive and gram-negative phathogenic microorganisms and a process for preparing the same, being characterized by cultivating Streptomyces tokunonensis sp. nov. in a suitable medium and recovering PA-31088-IV from the cultured broth.

Abstract: A novel process for preparing cephamycin C known antibiotic being useful as a medicament and veterinary drug, characterized by cultivating Streptomyces todorominensis sp. nov. in a suitable medium and recovering cephamycin C from the fermentation broth.